Clinical Trial Update: Phase 2A Study of GM 608 in Mild to Moderate Parkinson Disease [Phase 2]

View source ↗

Summary

Phase 2A study of GM 608 in mild to moderate Parkinson's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• GM 608

Snippet

Sponsor: Genervon Biopharmaceuticals, LLC | Conditions: Parkinson's Disease | Phase 2 | Status: COMPLETED